UNSPSC 51332832: Triflupromazine

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C18H19F3N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RO16TQF95Y, chemically known as 10h-phenothiazine-10-propanamine, n, n-dimethyl-2- (trifluoromethyl)-, monohydrochloride but generally known as triflupromazine, which bears US NIH Compound Identifier 5568. European Medicines Agency schedules Triflupromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11290MIG.

UNSPSC 51332832 Triflupromazine is a Commodity code that state and local governments use to classify pharmaceutical procurement, though recent opportunities tagged under this code show substantial divergence from the specific drug name. The work actually being solicited encompasses broader pharmaceutical supply and opioid-response product procurement—Naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing mechanisms, and direct-to-manufacturer prescription fulfillment programs for state pharmacy benefits. Issuing bodies span state health departments, county health systems, and multistate cooperative purchasing alliances; the Texas Health and Human Services Commission, Seminole County Florida, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear in recent activity. The work includes competitive bidding for specific quantities of anti-overdose and harm-reduction products, RFPs for pharmaceutical supply under cooperative frameworks, and exploratory RFIs for alternative pharmacy benefit delivery models.

Recent activity concentrates in Texas, Florida, and Minnesota. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of Naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Vendors typically must secure authorization from state-designated wholesalers, comply with FDA and Drug Supply Chain Security Act requirements, maintain specified insurance coverage, and submit detailed product data including National Drug Codes, packaging configurations, and manufacturing locations.